亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings

医学 结直肠癌 回顾性队列研究 肿瘤科 癌症 第一行 内科学
作者
Qun Zhang,Haiqing Niu,Ke Cheng,Xiaoping Qian
出处
期刊:Journal of gastrointestinal oncology [AME Publishing Company]
卷期号:16 (2): 542-548 被引量:1
标识
DOI:10.21037/jgo-2024-881
摘要

Background: Fruquintinib, a standard third-line treatment option for metastatic colorectal cancer (mCRC), has been shown to significantly prolong both overall survival (OS) and progression-free survival (PFS) in patients. However, we have observed that the standard dosing of fruquintinib is frequently associated with a higher incidence of adverse effects within the Chinese population, leading some patients-particularly elderly individuals-to be unable to tolerate it. This study presents a retrospective analysis to evaluate the therapeutic efficacy and safety of adjusting the administration frequency of fruquintinib in patients with mCRC. Methods: We conducted a retrospective analysis of the follow-up data and clinicopathological characteristics of 99 patients with mCRC who were treated with an adjusted frequency of furquinitinib administration at our center. We conduct regular imaging follow-ups and tumor marker evaluations to assess the therapeutic efficacy in patients. PFS data are collected through these assessments, while OS and adverse effects information is obtained via structured telephone follow-ups. Results: There were 99 patients with mCRC treated with fruquintinib monotherapy at an adjusted dosing frequency. The median progression-free survival (mPFS) for the 99 patients on fruquintinib monotherapy was 4.1 months and the median overall survival (mOS) was 11.4 months following the adjustment of dosing frequency, the overall response rate (ORR) was 2.0%, and the disease control rate (DCR) was recorded at 40.4% within the fruquintinib monotherapy. Overall, after receiving oral administration of fruquintinib at the modified frequency, no grade 3 or higher adverse reactions occurred in all patients. Conclusions: Our results showed that the administration of fruquintinib at an adjusted dosing frequency has not significantly impacted the efficacy while demonstrating a favorable safety profile. However, this conclusion necessitates further validation through prospective clinical trials with a larger sample size.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
3秒前
5秒前
8秒前
LJH发布了新的文献求助10
9秒前
9秒前
阳光元彤发布了新的文献求助10
10秒前
令狐大侠发布了新的文献求助30
11秒前
令狐大侠发布了新的文献求助10
11秒前
11秒前
专注凌柏发布了新的文献求助10
13秒前
令狐大侠发布了新的文献求助10
14秒前
充电宝的应助被xccccccc采纳,获得10
14秒前
令狐大侠发布了新的文献求助10
14秒前
令狐大侠发布了新的文献求助10
14秒前
令狐大侠发布了新的文献求助10
14秒前
令狐大侠发布了新的文献求助10
15秒前
LJH发布了新的文献求助10
18秒前
Alfred完成签到,获得积分10
19秒前
义气的夏旋完成签到,获得积分10
21秒前
阳光元彤完成签到,获得积分10
26秒前
LJH发布了新的文献求助10
26秒前
Alfred发布了新的文献求助10
28秒前
勤劳安波完成签到,获得积分10
29秒前
SUMI完成签到,获得积分10
30秒前
32秒前
xccccccc发布了新的文献求助10
36秒前
LJH发布了新的文献求助10
36秒前
37秒前
LJH发布了新的文献求助10
44秒前
49秒前
LJH发布了新的文献求助10
54秒前
务实老姆完成签到,获得积分10
54秒前
LJH发布了新的文献求助10
1分钟前
1分钟前
1分钟前
LJH发布了新的文献求助10
1分钟前
bai完成签到 ,获得积分10
1分钟前
youasheng发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185137
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834040
捐赠科研通 7782575
什么是DOI,文献DOI怎么找? 3434520
关于科研通互助平台的介绍 2558743
邀请新用户注册赠送积分活动 2481206